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Vascular endothelial growth factor (VEGF) is a key mediator of 
angiogenesis and critical for normal embryonic development 
and repair of pathophysiological conditions in adults. Al-
though phospholipase D (PLD) activity has been implicated in 
angiogenic processes, its role in VEGF signaling during angio-
genesis in mammals is unclear. Here, we found that silencing 
of PLD2 by siRNA blocked VEGF-mediated signaling in im-
mortalized human umbilical vein endothelial cells (iHUVECs). 
Also, VEGF-induced endothelial cell survival, proliferation, mi-
gration, and tube formation were inhibited by PLD2 silencing. 
Furthermore, while Pld2-knockout mice exhibited normal de-
velopment, loss of PLD2 inhibited VEGF-mediated ex vivo 
angiogenesis. These findings suggest that PLD2 functions as a 
key mediator in the VEGF-mediated angiogenic functions of 
endothelial cells. [BMB Reports 2016; 49(3): 191-196]
INTRODUCTION
VEGF signaling mediates an essential rate-limiting step of an-
giogenesis in endothelial cells (1, 2). From embryo to adult, 
angiogenesis plays key roles in development and basic life 
phenomena to maintain homeostasis of such vital functions as 
oxygen/nutrient supply and waste elimination (3, 4). Further-
more, an excess or shortage of angiogenesis affects various dis-
eases, such as cancer, inflammatory disorders, obesity, asthma, 
diabetes, multiple sclerosis, ischemic heart disease and pre- 
eclampsia (3-5). While VEGF is crucial for both physiological 
and pathological angiogenesis, it is dramatically upregulated 
during pathological angiogenesis, such as tumor and diabetic 
retinopathy (6, 7). Therefore, discovery and characterization of 
the key factor that mediates VEGF signaling in endothelial cells 
is essential for understanding the roles of angiogenesis in path-
ophysiological conditions.
Phospholipase D (PLD) is a phosphatidylcholine (PC)-hydro-
lyzing enzyme that generates phosphatidic acid (PA) and chol-
ine (8-11). In mammals, two PLD isozymes, PLD1 and PLD2, 
have been identified and have ∼50% sequence homology 
(8-11). PLD1 and PLD2 can be activated by a variety of up-
stream signals, such as growth factors, hormones, neuro-
transmitters, and phospholipids (8-11). PLD functions as a key 
amplifier/modulator between upstream signals and down-
stream mediators by producing the second messenger, PA. 
Recently, it has been reported that Src-dependent PLD1 is re-
quired for retinal neovascularization (12) and PLD1 is im-
plicated in the formation of intersegmental blood vessels in ze-
brafish (13). Although both PLD1 and PLD2 have been im-
plicated in numerous biological phenomena, including pro-
liferation, vesicle trafficking, cytoskeletal rearrangement, and 
differentiation (8-11), it is unknown how each PLD isozyme 
(PLD1 and PLD2) mediates VEGF signaling and whether either 
(especially PLD2) plays a key role in VEGF-mediated endothe-
lial cell functions and angiogenesis.
In this study, we investigated whether PLD1 and PLD2 me-
diate VEGF signaling in endothelial cells. We also determined 
whether PLD2 regulates the VEGF-mediated functions of endo-
thelial cells at the cellular and ex vivo tissue levels. Therefore, 
this study provides new information regarding the regulation 
of VEGF-induced angiogenesis. 
RESULTS
PLD isotype-specific signaling pathway in iHUVECs
PLD1 and PLD2 mediate not only similar functions, but also 
PLD isotype-specific functions (10, 11, 14-16). First, we inves-
tigated whether each PLD mediates isotype-specific angiogenic 
signaling in iHUVECs. After silencing of each PLD isotype, we 
assessed the activation of key mediators of angiogenesis in en-
dothelial cells. We found that both PLD1 and PLD2 silencing 
blocked phosphorylation of S-6-kinase and ERK in iHUVECs 
(Fig. 1A). However, silencing of PLD2, but not PLD1, reduced 
Src phosphorylation. In addition, when we investigated the ex-
pression levels of genes related to angiogenesis in iHUVECs af-
ter silencing of PLD1 or PLD2 (Fig. 1B and 1C), silencing of 
PLD2, but not PLD1, significantly decreased the ANGPT1 
mRNA level (Angiopoietin 1) (Fig. 1D). Furthermore, mRNA 
levels of KDR2 (VEGF receptor-2) and MMP2 (matrix metal-
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Fig. 2. PLD2 mediates VEGF signaling in iHUVECs. (A) iHUVECs were
starved for 24 h and then treated with VEGF (10 ng/ml) for the in-
dicated times. (B) iHUVECs were starved for 24 h and then treated
with various VEGF doses (0, 2, 5, 10, or 40 ng/ml) for 10 min. (C) 
Following siRNA silencing of PLD1 or PLD2, iHUVECs were starved
for 24 h and then treated with VEGF (10 ng/ml) for 10 min. The ly-
sates were analyzed via SDS-PAGE and Western blotting using the
indicated antibodies. Data are representative of at least two in-
dependent experiments. Bands were quantitatively analyzed by Image
J (NIH) program. Quantitation of each band is shown below.
Fig. 1. Regulation of angiogenic signaling mediators and expression 
of angiogenesis-related genes by PLD1 and PLD2. (A) Following 
siRNA silencing of PLD1 or PLD2, iHUVECs were cultured in growth
medium and then lysed with lysis buffer. The lysates were analyzed
by Western blotting using the indicated antibodies. Bands were 
quantitatively analyzed by Image J (NIH) program. Quantitation of 
each band is shown below. (B-F) Following transfection of iHUVECs
with siRNA against PLD1 or PLD2, total cDNA was isolated and the 
mRNA levels of specific genes (PLD1, PLD2, ANGPT1 (Angiopoietin
1), KDR2 (VEGF receptor-2) and MMP2) were measured by qPCR. 
Data are representative of at least two independent experiments.
Error bars indicate S.D. *P ＜ 0.05. N. S.: not significant.
loproteinase2) were reduced by silencing of PLD2, but not 
PLD1 (Fig. 1E and 1F). These results suggest that the role in an-
giogenesis of PLD2 differs from that of PLD1.
PLD2 is a key mediator of VEGF signaling in iHUVECs
VEGF as a key mediator of angiogenesis activates multiple in-
tracellular signaling pathways—including the phosphoinositide 
3-kinase (PI 3-kinase), AKT, ERK, and Src pathways—in endo-
thelial cells (1, 2). First, we investigated the roles of PLD iso-
types in VEGF-mediated signaling after siRNA silencing of 
PLD1 or PLD2 in iHUVECs. We verified that VEGF increased 
the phosphorylation of S-6-kinase, ERK, and Src in a time-de-
pendent manner (Fig. 2A), and a low VEGF concentration (2 
ng/ml) induced the phosphorylation of S-6-kinase, ERK, and 
Src in iHUVECs (Fig. 2B). PLD1 or PLD2 silencing blocked the 
VEGF-induced phosphorylation of ERK, S-6-kinase, and Src in 
iHUVECs (Fig. 2C). In particular, p-ERK and p-S-6-kinase levels 
were inhibited more significantly by PLD2 silencing than 
PLD1 silencing. In the case of Src, silencing of PLD2, but not 
PLD1, inhibited Src phosphorylation (Fig. 2C). These results 
suggest that PLD2 is essential for VEGF signaling in iHUVECs 
and that the VEGF-PLD2 pathway differs from the VEGF-PLD1 
pathway.
PLD2 deficiency leads to defects in VEGF-induced cell 
survival, proliferation, migration, and tube formation in 
iHUVECs
VEGF signaling mediates various endothelial cell functions— 
such as migration, proliferation, and survival—via multiple in-
tracellular signaling pathways including the Src, phosphoinosi-
tide 3-kinase (PI 3-kinase), AKT, and ERK pathways (1, 2, 4). 
Thus, we investigated the effect of PLD2 on the role of VEGF 
in the survival, proliferation, migration, and tube formation in 
iHUVECs. As shown in Fig. 3A and 3B, VEGF enhanced the 
survival and proliferation of iHUVECs. However, silencing of 
PLD2 blocked VEGF-induced cell survival and proliferation 
(Fig. 3A and 3B). Moreover, VEGF-induced migration and tube 
formation (in vitro angiogenesis) were also inhibited by silenc-
ing of PLD2 (Fig. 3C and 3D). Tube formation assay of in vitro 
angiogenesis has been reported to represent cell adhesion, mi-
gration, protease activation, and tubule formation in endothe-
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Fig. 3. PLD2 plays key roles in VEGF-induced iHUVEC survival, 
proliferation, migration and tube formation. (A and B) Following 
siRNA silencing of PLD2, iHUVECs were starved for 24 h and then
treated with VEGF (20 ng/ml) for 48 h. Cell viability was measured 
by MTT assay. Cells were enumerated using a hemocytometer. (C) 
Following siRNA silencing of PLD2, iHUVECs were starved for 24 h
and then detached. The detached cells were replated on the upper
well of a chemotaxis chamber. Chemotactic migration was meas-
ured in the absence or presence of VEGF (10 ng/ml). Scale bar, 100 
m. (D) Following siRNA silencing of PLD2, iHUVECs were starved
for 24 h and then detached. Cells were replated on matrigel-coated
dishes in the absence or presence of VEGF (40 ng/ml). The white 
arrows indicate intact branching points of network. The yellow ar-
rows indicate points where the branching network failed to occur. 
Scale bar, 250 m. Data are representative of at least two in-
dependent experiments. Error bars indicate S.D. *P ＜ 0.05.
Fig. 4. Aortas of Pld2-knockout mice show reduced VEGF-induced 
sprouting. (A) Mouse embryos and pups were genotyped at days 
E15.5 and P0, respectively. (B) Aortas were isolated from control 
and Pld2-knockout mice and implanted on matrigel. Aortas were 
treated with the indicated VEGF dose for the indicated time. Scale 
bar, 100 m. (C) Aortas were treated with VEGF (20 ng/ml) in the
absence or presence of 1-butanol or t-butanol. Scale bar, 100 m. 
(D) Aortas from control and Pld2-knockout mice were treated with
VEGF (40 ng/ml) for 5 days. Scale bar, 500 m. Data are repre-
sentative of at least two independent experiments.
lial cells (17). Multiple sequential steps—such as cell adhesion, 
survival, proliferation, and migration, protease activation, and 
tubule formation—in endothelial cells are critical for VEGF-in-
duced angiogenesis in vivo (1, 2, 4, 5). Therefore, these data 
imply that PLD2 contributes to angiogenesis through multiple 
processes such as VEGF-induced cell survival, proliferation, 
migration, and tubule formation.
PLD2 plays a role in VEGF-induced sprouting from aorta
Our in vitro data suggest that PLD2 might also mediate VEGF 
angiogenesis in vivo. We generated Pld2-knockout mice to re-
veal the roles of PLD2 in angiogenesis (18). First, we inves-
tigated the effect of PLD2 deficiency on tissue and organ 
development. As shown in Fig. 4A, at day E15.5, when fetal 
organogenesis was completed (19), we found that the geno-
types of fetuses exhibited a Mendelian ratio, as expected. 
Furthermore, mouse pups at P0 were born with a Mendelian 
ratio and showed normal development. Next, we investigated 
the effect of PLD2 deficiency on VEGF-induced angiogenesis. 
VEGF induces sprouting from mouse aorta in an ex vivo aortic 
ring assay, which is a more physiologically relevant model of 
angiogenesis and preserves certain key features of in vivo an-
giogenesis, which is mediated by various cell types (endothe-
lial cells, macrophages, pericytes, smooth muscle cells and fi-
broblasts) (20, 21). VEGF-induced endothelial cell (EC) sprout-
ing from the aorta occurred in a dose- and time-dependent 
manner (Fig. 4B). 1-Butanol, a blocker of PA generation from 
PLD, inhibited VEGF-induced EC sprouting from the aorta. 
However, t-butanol, as a control treatment, did not inhibit 
VEGF-induced EC sprouting (Fig. 4C). These results indicate 
that PLD activity is important for VEGF-mediated EC sprouting. 
When we investigated the involvement of PLD2 in ex vivo an-
giogenesis (aortic ring assay) using Pld2-knockout mice, we al-
so found that PLD2 deficiency inhibited VEGF-induced aortic 
sprouting (Fig. 4D). These data suggest that PLD2 is involved 
PLD2 is required for VEGF-induced angiogenesis
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in VEGF-mediated angiogenesis, although the cell-type specific 
roles of PLD2 in the aortic ring, which comprises multiple cell 
types, are unclear.
DISCUSSION
Here, we elucidated that PLD2 functioned as a key modulator 
of VEGF signaling pathways (ERK, S-6-kinase, and Src) in 
iHUVECs. This function of PLD2 was essential for survival, 
proliferation, migration, and tube formation of endothelial 
cells, which mediate new vessel formation or angiogenesis 
from existing vessels. Also, using an ex vivo Pld2-knockout 
mouse model, we revealed PLD2 to be an essential mediator 
of VEGF-mediated angiogenesis. Therefore, this work enhan-
ces our understanding of the intracellular mediators of VEGF- 
induced angiogenesis.
VEGF binds to and activates VEGF receptor-2 (VEGFR-2) on 
endothelial cells. VEGF binding induces the tyrosine phos-
phorylation of VEGFR-2 at multiple sites (Y951, Y1054, Y1059, 
Y1175, and Y1214) (2, 22-24). These tyrosine-phosphorylated 
sites recruit several downstream molecules—such as TSAd, 
Shb, Sck, and PLC—which mediate multiple functions—such 
as migration (Src or FAK pathway), survival (PI3 kinase-AKT- 
S-6-kinase pathway), proliferation (ERK pathway) and vascular 
permeability (eNOS pathway)—of endothelial cells (2, 22-33). 
Our results indicate that PLD2 silencing inhibits VEGF-induced 
phosphorylation of S-6-kinase, ERK, and Src in iHUVECs (Fig. 
2C). Thus PLD2 may play a role as a key regulator of these key 
mediators of angiogenesis (ERK, S-6-kinase, and Src). 
Recently, it has been reported that Src functions upstream of 
PLD1 in VEGF-mediated signaling of human retinal micro-
vascular endothelial cells (HRMVECs) (12). However, we 
found that PLD1 functioned upstream of Src in VEGF signaling 
and PLD1 silencing resulted in a slight increase in VEGF-in-
duced phosphorylation of Src compared to control silencing, 
while PLD2 silencing resulted in a reduction in VEGF-medi-
ated Src phosphorylation in iHUVECs (Fig. 2C). This result is 
in agreement with a previous report that silencing of PLD1 in-
creased the p-Src and p-Pyk2 levels, but PLD2 silencing had 
no significant effect (a slight reduction) on Src and Pyk2 phos-
phorylation in HeLa cells (14). Furthermore, mRNA levels of 
angiogenic related-genes were differently regulated by silenc-
ing of each PLD isotype in iHUVECs (Fig. 1D-F). Although 
whether these results are cell-type or signal specific is unclear, 
they suggest that PLD2 mediates VEGF signaling in a manner 
different from PLD1.
VEGF-neutralizing antibodies and VEGFR inhibitors have 
been used to target pathological angiogenesis, such as tumor 
angiogenesis (2, 34). However, as shown in knockout-mouse 
studies of VEGF and VEGFR, deficiency of these molecules 
caused embryonic lethality and defects in organ development 
due to failure of angiogenesis (2, 34-39). These data indicate 
that molecules that target VEGF and VEGFR may affect physio-
logical angiogenesis. Here, we found that Pld2-knockout mice 
were born normally (a Mendelian frequency) (Fig. 4A). There-
fore, PLD2 did not critically affect normal development and 
physiological angiogenesis. However, PLD2 deficiency in-
hibited VEGF (40 ng/ml)-mediated ex vivo angiogenesis (Fig. 
4D). In mouse and human, the physiological level of VEGF is 
∼0.065 ng/ml and 0.137 ng/ml, respectively (40, 41). In 
pathological tissue such as tumors, the VEGF level is 10-200 
fold higher than that in normal tissue (42). Taken together, 
these reports and our findings suggest that PLD2 plays a key 
role in a high local concentration of VEGF, such as in patho-
logical conditions. Therefore, we suggest that angiogenic tar-
geting of PLD2, which is a key downstream molecule of VEGF 
signaling, may facilitate development of a drug targeted specif-
ically at pathological conditions, while not negatively affecting 
the overall physiological condition.
MATERIALS AND METHODS
Animal
All mice were kept in an animal facility at the Pohang 
University of Science and Technology (POSTECH). Animal ex-
periments were performed according to the institutional guide-
lines of POSTECH. To generate whole-body Pld2-knockout 
(KO) mice, Pld2fl/fl mice were crossed with Protamine-Cre 
(Jackson Laboratory) and Pld2 KO mice then maintained with-
out the Cre allele. Pld2 KO mice were backcrossed with 
C57BL/6 for at least 14 generations.
Cell culture and transfection
Immortalized iHUVECs were maintained at 37oC in 5% CO2 
in M199 medium supplemented with 10% FBS (Lonza), 5 mM 
L-glutamine (Life Technologies), endothelial cell growth sup-
plement (BD Biosciences), penicillin (100 units/ml) and strep-
tomycin (0.1 mg/ml). For PLD silencing, iHUVECs were trans-
fected with control siRNA (luciferase GL2 duplex; Dharmacon 
Research) or PLD1 and/or PLD2 siRNA (20 nM duplex) using 
Lipofectamine (Invitrogen) according to the manufacturer’s in-
struction and then cultured for 48 h. 
Western blotting
Samples were lysed in lysis buffer (20 mM Tris/pH 8.0, 150 
mM NaCl, 1 mM EDTA, 0.1% SDS, 1.0% Triton X-100, 1.0% 
sodium deoxycholate, and protease inhibitor cocktail (Sigma)). 
After centrifugation at 10,000 × g for 10 min at 4oC, the pro-
tein concentration of supernatants was determined by Bradford 
assay. Laemmli sample buffer (5X) was added to the samples, 
which were then separated by SDS-PAGE and transferred onto 
nitrocellulose membranes (0.2 m pore size). The membranes 
were blocked in blocking solution (5% non-fat milk in TTBS), 
then incubated with primary antibodies for 4 h or overnight at 
room temperature, followed by incubation with secondary anti-
bodies (horseradish peroxidase (HRP)-conjugated) for 1 h. Blots 
were detected using an enhanced chemiluminescence kit.
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Quantitative PCR (qPCR)
Total RNA from iHUVECs was isolated using TRIzol reagent, 
and cDNAs were generated from 1 g of total RNA. qPCR was 
performed with HotStart-IT SYBRⓇ Green and a Bio-Rad iCycler 
iQ instrument using specific primers (PLD1 (F:TGCGTCTACA 
TCCCAACATAAA, R:AGGTCAATCCCTCCCACAA), PLD2 (F: 
GCTCCCCTTCACACTTCCAG, R:GCAGGTAGGCATTGAGGA 
TG), ANGPT1 (F:GACAGCAGGAAAACAGAGCAG, R: CACA 
AGCATCAAACCACCATC), KDR2 (F:CAGAGTTGGTGGAACA 
TTTGG, R:CAGGAAACAGGTGAGGTAGGC), MMP2 (F:TACC 
CCAAGCCACTGACCA, R:ACGACGGCATCCAGGTTAT)). The 
relative mRNA quantities were calculated by the comparative 
Ct method after normalization to GAPDH.
MTT assay
MTT assay were performed as previously described, with some 
modifications (43). Cells were plated in 12-well plates and 
transfected with control or PLD2 siRNA using Lipofectamine 
(Invitrogen). After culturing for a further 2 days, cells were 
starved for 24 h and then treated with VEGF (20 ng/ml) for 48 
h. Tetrazolium dye, MTT (0.5 mg/ml) was added to each well 
and the plates were incubated for 4 h at 37oC. Remaining MTT 
was removed and DMSO was added to each well to dissolve 
formazan crystals. Absorbance at 540 nm was measured using 
a spectrophotometer.
Proliferation
Cells were plated in six-well plates and transfected with con-
trol or PLD2 siRNA using Lipofectamine (Invitrogen). After be-
ing cultured for a further 2 days, cells were starved for 24 h 
and then treated with VEGF (20 ng/ml) for 48 h. For enumera-
tion, cells were detached with trypsin and then counted using 
a hemocytometer.
Migration
Cell migration was measured using a modified Boyden chemo-
taxis chamber (NeuroProbe Inc.) as previously described, with 
some modifications (44). Polycarbonate membranes (8 m 
pore size) were coated with collagen (20 g, Sigma). Culture 
medium containing VEGF (10 ng/ml) was added to the bottom 
wells of the chamber. After starvation for 24 h, cells were de-
tached and then resuspended in serum-free medium. The cells 
in the upper chamber were plated at a density of 1 × 104 cells. 
The chambers were incubated at 37oC for 3 h. Non-migrating 
cells in the upper chamber were removed from the membrane, 
and migrated cells were stained with Hoechst dye (Sigma).
Tube formation
After starvation for 24 h, iHUVECs (1 × 105 per well) were 
plated into 48-well culture plates coated with growth factor-re-
duced matrigel (BD Biosciences) and then incubated for 9 h at 
37oC in M199 medium containing VEGF (40 ng/ml). Images 
were obtained using a Zeiss Axiovert 135 microscope.
Aortic ring assay
After euthanasia, mice were perfused with cold PBS (10 ml) 
containing 1% FBS. The aortic ring was excised from each 
mouse and cut into 1 mm lengths. The aortic rings were im-
planted in growth factor reduced Matrigel (BD Biosciences) 
and incubated with EBM-2 medium supplemented with VEGF 
(20 or 40 ng/ml) for 5 days.
Statistical analysis
The data are presented as means ± SD. Statistical analyses 
were performed using Student’s t-test. * P ＜ 0.05.
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